title: [Effect of 5'-DFUR used concurrently in radiotherapy and immunotherapy uterine cervical cancer--pilot study. Study of 5'-DFUR for Uterine Cervical Cancer].
abstract: We conducted a preliminary controlled study in order to evaluate 5'-DFUR dose dependency in efficacy and safety in combination therapy of radiotherapy, 5'-DFUR and SPG for patients with uterine cervical cancer, which was regarded as suitable for cases of radiotherapy. The patients were randomly allocated into group A (5'-DFUR 600 mg/body/day) and group B (5'-DFUR 800 mg/body/day), who underwent radiotherapy with simultaneous administration of 5'-DFUR and SPG (20 mg twice/week or 40 mg/ week). Those enrolled were 33 patients in stage II, III or IV a with histologically diagnosed primary squamous cell carcinoma of uterine cervix. CR was shown in 19, PR in 7, NC in 1, and PD in 2 out of 29 efficacy-evaluable cases, so the overall response rate was 89.7% (26/29, 95% CI 72.7%-97.8%). Regarding safety, some side effects were observed in 26 out of 33 safety-evaluable cases (81.3%, 95%, CI 63.6%-92.8%), but no serious cases. No significant difference in efficacy and safety was observed between the two treatment groups. These results suggested that the combination therapy of radiotherapy, 5'-DFUR and SPG might be one of the therapies whose effectiveness must be confirmed for advanced squamous cell carcinoma of uterine cervix. To confirm dose dependency of 5'-DFUR, it seems further consideration with more patients is needed.
authors.affiliation: Dept. of Obstetrics and Gynecology, Kagoshima City Hospital.
authors.forename: M
authors.initials: M
authors.lastname: Hatae
authors.forename: K
authors.initials: K
authors.lastname: Noda
authors.forename: A
authors.initials: A
authors.lastname: Yajima
authors.forename: S
authors.initials: S
authors.lastname: Sato
authors.forename: Y
authors.initials: Y
authors.lastname: Terashima
authors.forename: K
authors.initials: K
authors.lastname: Ochiai
authors.forename: H
authors.initials: H
authors.lastname: Sasaki
authors.forename: K
authors.initials: K
authors.lastname: Mizutani
authors.forename: H
authors.initials: H
authors.lastname: Honjo
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.forename: M
authors.initials: M
authors.lastname: Ozaki
authors.forename: K
authors.initials: K
authors.lastname: Yamamoto
authors.forename: K
authors.initials: K
authors.lastname: Hasegawa
authors.forename: R
authors.initials: R
authors.lastname: Nishimura
authors.forename: T
authors.initials: T
authors.lastname: Kudo
authors.forename: Y
authors.initials: Y
authors.lastname: Kobashi
authors.forename: M
authors.initials: M
authors.lastname: Yakushiji
authors.forename: T
authors.initials: T
authors.lastname: Sugiyama
authors.forename: Y
authors.initials: Y
authors.lastname: Hasuo
authors.forename: Y
authors.initials: Y
authors.lastname: Onishi
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy / Q000628:therapy; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage*; D006801:Humans; D007167:Immunotherapy; D008875:Middle Aged; D010865:Pilot Projects; D012566:Sizofiran / Q000008:administration & dosage*; D002583:Uterine Cervical Neoplasms / Q000532:radiotherapy* / Q000628:therapy*
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D005467:Floxuridine; D012566:Sizofiran; C025034:doxifluridine